Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 5/20 | 0.58 |
| ▸ | HPGD | P15428 | 4/20 | 0.58 |
| ▸ | KMT2A | Q03164 | 6/20 | 0.50 |
| ▸ | MEN1 | O00255 | 5/20 | 0.50 |
| ▸ | POLB | P06746 | 3/20 | 0.50 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.47 |
| ▸ | NPC1 | O15118 | 2/20 | 0.47 |
| ▸ | RAB9A | P51151 | 2/20 | 0.47 |
| ▸ | XBP1 | P17861 | 1/20 | 0.47 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.47 |
| ▸ | MAPT | P10636 | 6/20 | 0.44 |
| ▸ | RRM1 | P23921 | 3/20 | 0.43 |
| ▸ | L3MBTL1 | Q9Y468 | 4/20 | 0.43 |
| ▸ | GAA | P10253 | 3/20 | 0.42 |
| ▸ | ATM | Q13315 | 1/20 | 0.42 |
| ▸ | ERN1 | O75460 | 1/20 | 0.42 |
| ▸ | THRB | P10828 | 2/20 | 0.41 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.41 |
| ▸ | TSHR | P16473 | 1/20 | 0.41 |
| ▸ | MPI | P34949 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23087651 | 1.00 | KDM4E (0.58) | KDM4EHPGDKMT2AMEN1POLB | |
| SCHEMBL3073849 | 0.81 | KDM4E (0.58) | KDM4EHPGDKMT2AMEN1POLB | |
| SCHEMBL3073851 | 0.81 | KDM4E (0.58) | KDM4EHPGDKMT2AMEN1POLB | |
| SCHEMBL3072667 | 0.79 | MAPT (0.67) | KDM4EHPGDKMT2AMEN1POLB | |
| SCHEMBL3072670 | 0.79 | MAPT (0.67) | KDM4EHPGDKMT2AMEN1POLB | |
| SCHEMBL2449884 | 0.76 | HPGD (0.56) | KDM4EHPGDKMT2AMEN1POLB | |
| SCHEMBL17988287 | 0.76 | HPGD (0.56) | KDM4EHPGDKMT2AMEN1POLB | |
| SCHEMBL16538613 | 0.75 | KDM4E (0.55) | KDM4EHPGDKMT2AMEN1POLB | |
| SCHEMBL2786544 | 0.75 | ERN1 (0.60) | KDM4EKMT2AMEN1POLBALDH1A1 | |
| SCHEMBL5496995 | 0.75 | ALDH1A1 (0.44) | KDM4EHPGDKMT2AMEN1POLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240208912-A1 | MTA-Cooperative PRMT5 Inhibitors | MIRATI THERAPEUTICS INC (US) | 2024-06-27 | — | — | US | disclosed |
| EP-4304720-A1 | MTA-COOPERATIVE PRMT5 INHIBITORS | Mirati Therapeutics, Inc. (US) | 2024-01-17 | — | — | EP | disclosed |
| US-20230054883-A1 | MTA-Cooperative PRMT5 Inhibitors | Mirati Therapeutics, Inc. | 2023-02-23 | — | — | US | disclosed |
| US-11492351-B2 | MTA-cooperative PRMT5 inhibitors | Mirati Therapeutics, Inc. (US) | 2022-11-08 | — | — | US | disclosed |
| US-11479551-B2 | MTA-cooperative PRMT5 inhibitors | Mirati Therapeutics, Inc. (US) | 2022-10-25 | — | — | US | disclosed |
| WO-2022192745-A1 | MTA-COOPERATIVE PRMT5 INHIBITORS | Mirati Therapeutics, Inc. (US) | 2022-09-15 | — | — | WO | disclosed |
| EP-4028388-A1 | MTA-COOPERATIVE PRMT5 INHIBITORS | Mirati Therapeutics, Inc. (US) | 2022-07-20 | — | — | EP | disclosed |
| CN-114728912-A | MTA-synergistic PRMT5 inhibitors | 米拉蒂医疗股份有限公司 | 2022-07-08 | — | — | CN | disclosed |
| US-20210078994-A1 | MTA-Cooperative PRMT5 Inhibitors | Mirati Therapeutics, Inc. | 2021-03-18 | — | — | US | disclosed |
| WO-2021050915-A1 | MTA-COOPERATIVE PRMT5 INHIBITORS | Mirati Therapeutics, Inc. (US) | 2021-03-18 | — | — | WO | disclosed |
| US-20210079003-A1 | MTA-Cooperative PRMT5 Inhibitors | Mirati Therapeutics, Inc. | 2021-03-18 | — | — | US | disclosed |
| EP-2379544-A1 | ISOXAZOLINES DERIVATIVES AND THEIR USE AS PESTICIDE | Novartis AG (CH) | 2011-10-26 | — | — | EP | disclosed |
| WO-2010079077-A1 | ISOXAZOLINES DERIVATIVES AND THEIR USE AS PESTICIDE | NOVARTIS AG (CH) | 2010-07-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11479551-B2 | MTA-cooperative PRMT5 inhibitors | PRMT5, PRMT1, PRMT3 | KDM4E 143/4885HPGD 2337/4885KMT2A 139/4885 |
| US-20240208912-A1 | MTA-Cooperative PRMT5 Inhibitors | PRMT1, PRMT5, PRMT6 | KDM4E 644/4885HPGD 3263/4885KMT2A 165/4885 |
| US-20210079003-A1 | MTA-Cooperative PRMT5 Inhibitors | PRMT5, PRMT1, PRMT3 | KDM4E 122/4885HPGD 2554/4885KMT2A 109/4885 |
| US-20210078994-A1 | MTA-Cooperative PRMT5 Inhibitors | PRMT5, PRMT1, PRMT3 | KDM4E 122/4885HPGD 2554/4885KMT2A 109/4885 |
| US-11492351-B2 | MTA-cooperative PRMT5 inhibitors | PRMT5, PRMT1, PRMT3 | KDM4E 143/4885HPGD 2337/4885KMT2A 139/4885 |
| US-20230054883-A1 | MTA-Cooperative PRMT5 Inhibitors | PRMT5, PRMT1, PRMT3 | KDM4E 122/4885HPGD 2554/4885KMT2A 109/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.